Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
Amikacin disulfate salt
Product Details | |
---|---|
Synonyms | Amikacin disulfate; Biodacyn; Selemycin; Amiglyde; BB-K 8; Novamin; Amikin |
Product Type | Chemical |
Properties | |
Formula | C22H43N5O13 . 2H2SO4 |
MW | 781.76 |
CAS | 39831-55-5 |
RTECS | WK1961200 |
Source/Host Chemicals | Synthetic. |
Purity Chemicals | ≥97% (NMR) |
Appearance | White to off-white powder. |
Solubility | Soluble in water (50mg/ml). |
Identity | Determined by 1H-NMR. |
Declaration | Manufactured by Chemodex. |
Other Product Data |
Click here for Original Manufacturer Product Datasheet |
InChi Key | FXKSEJFHKVNEFI-GCZBSULCSA-N |
Smiles | OS(O)(=O)=O.OS(O)(=O)=O.O[C@@H]([C@@H]([C@H]1N)O[C@H]([C@@H]([C@H]2O)O)O[C@H](CN)[C@H]2O)[C@H]([C@@H](C1)N([H])C([C@H](CCN)O)=O)O[C@H]([C@@H]([C@H]3N)O)O[C@H](CO)[C@H]3O |
Shipping and Handling | |
Shipping | AMBIENT |
Short Term Storage | +20°C |
Long Term Storage | +4°C |
Handling Advice | Protect from light and moisture. |
Use/Stability | Stable for at least 2 years after receipt when stored at +4°C. |
Documents | |
MSDS | Inquire |
Product Specification Sheet | |
Datasheet | Download PDF |
Amikacin is a broad-spectrum aminoglycoside antibiotic and a semisynthetic analog of kanamycin. It irreversibly binds to 16S rRNA and the RNA-binding S12 protein of the 30S subunit and 50S subunit of prokaryotic ribosome and inhibits protein synthesis. It works in a concentration-dependent manner, and has better action in an alkaline environment. Amikacin disulfate is very active against most Gram-negative bacteria including gentamicin- and tobramycin-resistant strains, due to its resistance to inactivating enzymes. Amikacin disulfate also inhibits the infections caused by susceptible Nocardia and nontuberculous mycobacteria. Amikacin can be used to treat non-tubercular mycobacterial infections and tuberculosis when first-line drugs fail to control the infection.
[1] H. Kawaguchi, et al.; J. Antibiot. 25, 695 (1972) | [2] P.K. Yu, et al.; Antimicrob. Agents Chemother. 4, 133 (1973) | [3] D. Zaske & K. Crossley; Minn. Med. 61, 123 (1978) (Review) | [4] F.D. Pien & P.W. Ho; Am. J. Hosp. Pharm. 38, 981 (1981) (Review) | [5] A.M. Ristuccia & B.A.Cunha; Ther. Drug Monit. 7, 12 (1985) (Review) | [6] M.S. Ramirez & M.E. Tolmasky; Molecules 22, 2267 (2017) (Review)